1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Hemostemix Inc.
  6. News
  7. Summary
    HEM   CA4236943060

HEMOSTEMIX INC.

(HEM)
Delayed Bourse de Toronto  -  05/27 02:42:01 pm EDT
0.3300 CAD    0.00%
05/20Hemostemix Reports Non-Brokered Private Placement; Down 8.6%
MT
05/19HEMOSTEMIX : Announces Financing
PU
05/19Hemostemix Inc. announced a financing transaction
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hemostemix Announces Soft Lock of Database as Source Document Verification Completed

12/09/2021 | 11:09am EDT

Hemostemix Inc. announced the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal investigators, the HS 12-01 database will be locked. The database includes a total of 65 subjects who were randomized on a 2:1 basis to receive ACP-01 or a placebo, respectively. The Company is seeking the return of all of its intellectual property and assets from Aspire Health Sciences, LLC, including the randomization key(s) required to complete the statistical analyses of the trial.


© S&P Capital IQ 2021
All news about HEMOSTEMIX INC.
05/20Hemostemix Reports Non-Brokered Private Placement; Down 8.6%
MT
05/19HEMOSTEMIX : Announces Financing
PU
05/19Hemostemix Inc. announced a financing transaction
CI
05/03Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
05/03Hemostemix Inc. Auditor Raises 'Going Concern' Doubt
CI
04/25Hemostemix Closes $2.75 Million Debenture Offering
MT
04/25Hemostemix Inc. announced that it has received CAD 2.75 million in funding
CI
03/02Hemostemix Up 5.7% after Reporting Private Placement of Convertible Debentures
MT
03/02Hemostemix Inc. announced that it expects to receive CAD 2.75 million in funding
CI
02/28Hemostemix Inc. announced that it has received CAD 1.20485 million in funding
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 22,5 M 17,7 M 17,7 M
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 85,3%
Chart HEMOSTEMIX INC.
Duration : Period :
Hemostemix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Thomas A. Smeenk President, Chief Executive Officer & Director
Christina Wu Chief Financial Officer
Peter Alan Lacey Chairman
Fraser C. Henderson Chief Medical Officer
Peter Pavlin Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
HEMOSTEMIX INC.106.25%18
GILEAD SCIENCES, INC.-10.76%80 866
REGENERON PHARMACEUTICALS, INC.9.70%73 638
VERTEX PHARMACEUTICALS24.65%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-22.01%37 870